Abstracts tagged "PD-1"

Abstract Number: 1403 • 2015 ACR/ARHP Annual Meeting
Immune Related Adverse Events Associated with Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review of Case Reports
Noha Abdel-Wahab^1,2 and Maria E. Suarez-Almazor³, ¹Rheumatology & Rehabilitation Department, Assiut University Hospital, Egypt, Assiut, Egypt, ²The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, USA, Houston, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Background: The recent discovery of the immune checkpoint blockade that targets the regulatory pathways in T cells to enhance antitumor immune responses has led…
Abstract Number: 1760 • 2015 ACR/ARHP Annual Meeting
PD-1 Signaling Interferes with OX40 to Alter the Suppressive Function and Proliferation of CD4+ Regulatory T Cells in Lupus Mice
Maida Wong¹ and Bevra H. Hahn^2,3, ¹Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, ²Medicine, UCLA David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ³Rheumatology, Professor Emeritus, Department of Medicine/Rheumatology, David Geffen School of Medicine UCLA, Los Angeles, CA
Background/Purpose: In systemic lupus erythematosus (SLE), the dysregulated production of autoantibodies is a consequence of disrupted T cell homeostasis. Programmed death-1 (PD1), a negative regulatory…
Abstract Number: 2529 • 2015 ACR/ARHP Annual Meeting
Decreased Programmed Death Ligand-1 (PD-L1) in Systemic Lupus Erythematosus (SLE) Placenta
Gail Deutsch^1,2, Megan Yuasa³ and Anne M. Stevens^4,5, ¹Pathology, Seattle Children's Hospital, Seattle, WA, ²School of Medicine, University of Washington, Seattle, WA, ³Seattle Children's Res Institute, Seattle Children's Research Institute, Seattle, WA, ⁴Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA, ⁵Pediatrics, University of Washington, Seattle, WA
Background/Purpose: The increased rates of preeclampsia, preterm birth, and intrauterine growth restriction in SLE pregnancy are only partially explained by the vascular effects of anti-phospholipid…
Abstract Number: 2729 • 2014 ACR/ARHP Annual Meeting
To Live or Let Die… the Battle Between PD-1 and OX40 on SLE T Cells
Julie Kristine Laustsen¹, Stinne Greisen², Bent Deleuran³ and Tue Kruse Rasmussen⁴, ¹Aarhus University, Aarhus C, Denmark, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Dept of Biomedicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Programmed cell death 1 (PD-1) is a co-inhibitory receptor, which inhibits T cell proliferation and survival by inhibiting IL-2 signalling. By this PD-1 has…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].